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Background: Estrogen is believed to play an important role in the central nervous system (CNS) and exert a
protective role against schizophrenia. Estrogen receptor alpha (ESRα) mediates the biological action of estrogen.
Rs2234693 and rs9340799, single nucleotide polymorphisms of ESRα, may be related to many psychiatric disorders,
while their association with schizophrenia has not been clarified.
Methods: Genotypes rs2234693 and rs9340799 were detected in 303 schizophrenic patients and 292 healthy
controls in a Chinese population. The positive and negative syndrome scale (PANSS) was used to estimate
symptoms and therapeutic effects. The association of these polymorphisms with schizophrenia and clinical
characteristics was analyzed by the chi-square test, analysis of variance, and others.
Results: The distribution of genotypes and allele frequencies of rs2234693 and rs9340799 exhibited no significant
differences between patients and controls, while haplotypes consisting of these polymorphisms had significant
differences. For 2234693, T-allele carriers had an earlier age at onset. CC-homozygote carriers had a higher general
psychopathology score and its percentage reduction in male and paranoid patients, respectively. CC-homozygote
carriers had a higher tension (G4) and poor impulse control (G14) score, mainly in paranoid patients. Furthermore,
patients with the CC homozygote had higher reductions of G4 and G14 scores when treated by aripirazole and
risperidone, respectively.
Conclusions: Haplotypes consisting of these two polymorphisms in ESRα may be strongly associated with
schizophrenia. The rs2234693 was related to age at onset, general psychopathology, G4 and G14 symptoms, even
the therapeutic effect in different groups.
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Schizophrenia is a severe and polygenic inherited disease
with an incidence of appropriately 1% worldwide [1].
The mechanism of its pathogenesis has been explored in
various studies, but it is still undefined. Some psychiatric
clinical data show the obvious differences between the* Correspondence: lwq781603@163.com; lvx928@126.com
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reproduction in any medium, provided the ortwo genders in age at onset, symptomatology, and prog-
nosis for schizophrenia [2]. The peak age of onset for fe-
males is 4 to 6 years later than that of males [3].
Furthermore, affective symptoms are more prevalent in
female patients [4], while functional impairment is more
likely present in males [5]. In addition, female patients
have a better overall prognosis than males [6].
The gender differences might be explained by the
modern estrogen hypothesis, which presupposes that es-
trogen exerts a protective activity against schizophrenia
[7]. The ovarian steroid hormone estrogen plays antd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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on the CNS has been fully described [8,9]. The estro-
genic level fluctuation was in different genders and ages,
which has long been demonstrated [10,11]. On the other
hand, patients with an older age at onset may live with a
decreasing estrogenic level [10]. The cognitive abilities
of patients with higher estrogenic levels are better than
those with lower levels [12]. Furthermore, a previous
study has found that the positive effect of estrogen treat-
ment with standardized antipsychotic medication may
be effective in replacement therapy for female schizo-
phrenia [13].
The biological actions of estrogen are manifest through
estrogen receptors, which belong to a large family of nu-
clear receptors [14]. Two estrogen receptors have been
identified, designated as estrogen receptor alpha (ESRα)
and estrogen receptor beta (ESRβ) [14]. ESRα localizes in
chromosome 6 and encodes a 6.8-kilobase mRNA
containing eight exons, finally becoming transformed into
diverse proteins with different binding abilities [15], while
ESRβ localizes in chromosome 14 and encodes a protein
which is 97% and 59% homologous in the amino acid se-
quence with ESRα in DNA- and hormone-binding do-
mains, respectively [16]. The distribution and biological
activation of the two estrogen receptors in the nervous
system are generally consistent [17], but ESRα appears to
be responsible for most of the known estrogenic activa-
tions [18].
Recent studies have determined that the single nucleo-
tide polymorphisms (SNPs) of ESRα might be related to
many disorders, including osteoporosis [19], stroke [20],
and Alzheimer’s disease [21]. Interestingly, other studies
have indicated that the SNPs in ESRα are also associated
with many psychiatric disorders. A case–control study
showed a significant association of ESRα SNP rs2234693
with major depression disorder [22]. Furthermore, the
ESRα haplotypes created by rs2234693 and rs9340799
polymorphisms increased the likelihood of having an
anxiety disorder but not a depressive disorder [23].
Schizophrenia is a highly heterogeneous disease effected
by multiple genes that generally belong to different hy-
pothesis for the etiology of this disorder [24], such as
the dopamine D2 receptor gene, a key member of dopa-
mine hypothesis for schizophrenia, whose polymor-
phisms are associated with schizophrenia [25]. Based on
the estrogen hypothesis, Weickert et al. [26] reported
that rs2234693 was related to ESRα mRNA levels, asso-
ciating with schizophrenia in their African American
case–control sample, but other studies [27,28] had dif-
ferent point of view.
Overall, the conclusions of association between ESRα
and schizophrenia are inconsistent. The purpose of this
study was to determine whether there exists an associ-
ation of ESRα polymorphisms with schizophrenia in oursamples. Furthermore, we also examined the association
of the polymorphisms with clinical characteristics in-
cluding age at onset, symptoms, and therapeutic effects.
Materials and methods
Subjects
Three hundred three inpatients with schizophrenia
(male/female = 152/151) were recruited from the Second
Affiliated Hospital of Xinxiang Medical University. The
patients were diagnosed in accordance with Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edi-
tion (DSM-IV) criteria by at least two experienced psy-
chiatrists on the basis of structured clinical interviews
and medical records. Patients were treated by monother-
apy with aripiprazole (Abilify) (n = 146) or risperidone
(Risperdal) (n = 157) after a washout period of 6 weeks.
The average daily dose of antipsychotics for each patient
was 4.9 ± 1.6 mg/day in risperidone equivalents.
Two hundred ninety-two healthy controls (male/
female = 146/146) without a psychiatric history (in-
cluding personal and family) and complex disorders
including diabetes, hypertension, immunological me-
diated disease, and tumors were selected from local Henan
Province. All participators in the study were Chinese
Hans. The mean age of the case group was 29.99 ± 8.86,
and that of the control group was 30.92 ± 9.12. No signifi-
cant differences in sex or age between the two groups
existed.
All subjects consented to participate in the study after
reviewing the informed consent. The study was ap-
proved by the Institutional Review Board of the Second
Affiliated Hospital of Xinxiang Medical University.
Clinical measures
The age at which the individual first experienced a diag-
nosis or symptoms of schizophrenia was defined as the
age at onset of schizophrenia. To assess the psychopath-
ologic severity of the patients, PANSS (including 3 sub-
scales, positive symptom, negative symptom and general
psychopathology symptom) was used by four experi-
enced psychiatrists. The severity of each symptom was
scored with one of seven grades (1 = absent, 2 = min-
imal, 3 = mild, 4 = moderate, 5 = moderate severe, 6 =
severe, 7 = extreme). The PANSS scores at week 0 were
regarded as baseline. To evaluate the therapeutic effect
over 6 weeks, the percentage reduction in PANSS score
and reduction in PANSS subscore were used. All the
psychiatrists had been trained in the use of PANSS be-
fore the study.
Genotyping
Global genomic DNA was extracted from the peripheral
leucocytes using standard protocols. The ESRα fragment,
including rs2234693 and rs9340799 polymorphisms, was
Wang et al. Behavioral and Brain Functions 2013, 9:12 Page 3 of 8
http://www.behavioralandbrainfunctions.com/content/9/1/12amplified by the polymerase chain reaction (PCR) with
the following primers: Sense: 50-CCTTTCTGTGTTCCT
CTTCT-30; antisense: 50-TACCTCTTGCCGTCTGTT-30.
PCR amplification was performed in a 25-μL reaction vol-
ume containing 10 × PCR buffer (supplied by Tian Gen)
2.5 μL, dNTP mix (2.5 mM, supplied by Tian Gen) 0.5 μL,
sense primer (10 μM, supplied by Genewiz) 1 μL, anti-
sense primer (10 μM, supplied by Genewiz) 1 μL, genomic
DNA 1 μL, Taq DNA polymerase (5 U/μL, supplied by
Tian Gen) 0.4 μL, and sterile deionized water 18.6 μL.
After initial denaturation at 94°C for 5 min, the ingredi-
ents were mixed at 35 cycles at 94°C for 30 s, 55°C for
30 s, 72°C for 54 s, and a final elongation was done at
72°C for 10 min. The PCR product was cleaved using
Pvu II and Xba I restriction enzymes (supplied by
Thermo) at 37°C for 2 h, then analyzed by electrophor-
esis on 1.5% agarose gels. Genotypes for rs2234693
and rs9340799 polymorphisms were identified by two
investigators independently.
Statistical analysis
Hardy Weinberg equilibrium was performed using
Haploview 4.1 to examine the genotype distributions of
these two polymorphisms of ESRα. The strength of linkage
disequilibrium between the two SNPs was determined
using D’ and r2 algorithm testing by SHEsis online soft-
ware (http://analysis2.bio-x.cn/myAnalysis.php) [29]. The
Kaplan-Meier method and the log-rank test for analysis of
survival were used to examine the association of age at
onset with the two polymorphisms [30]. The difference in
genotypic and allelic frequency distribution between case
and control groups was estimated by SPSS software 18.0
using the Pearson chi-square (χ2) test. Haplotype analysis
for the ESRα was performed using SNPStats software on
line (http://bioinfo.iconcologia.net/snpstats) [31]. The re-
lationship between the polymorphisms and the clinical
variables was also analyzed by SPSS 18.0 using one-way
ANOVA or rank sum test. In addition, to control for the
possible confounding effect of gender and therapeutic
drugs, stratification of the samples was repeated by those
factors, respectively [32]. The Bonferroni correction was




N HWE (p) Genotype MAF
rs2234693 TT TC CC
All 303 0.55 109 150 44 0.15
Male 152 0.86 63 71 18 0.12
Female 151 0.51 46 79 26 0.17
rs9340799 AA AG GG
All 303 1.00 194 97 12 0.04
Male 152 0.50 91 51 10 0.07
Female 151 0.37 103 46 2 0.01
Boldface letters represent that the Bonferroni corrected p-values are still less than 0power analysis was performed using the Genetic Power
Calculator [33]. All statistical analyses were two-tailed,




The PCR products were 899 base pairs. The three geno-
types resulting from digestion with Pvu II were CC
(899 bp), CT (899, 630, 269 bp), and TT (630, 269 bp).
Similarly, three genotypes were yielded from digestion
with Xba I: GG (899 bp), AG (899, 675, 224 bp), and AA
(675, 224 bp). The codominant model was a combin-
ation of separate genotypes of CC, CT, and TT for
rs2234693, and AG, GG, and GG for rs9340799. The
dominant model consisted of a C-allele carrier and TT
homozygote for rs2234693, and a G-allele carrier and
AA homozygote for rs9340799. Furthermore, the reces-
sive model was formed by a T-allele carrier and CC
homozygote for rs2234693, and an A-allele carrier and
GG homozygote for rs9340799.
Association of SNPs with schizophrenia
The distributions of genotypes and allele frequencies of
the ESRα polymorphisms for all, male, and female
groups were in Hardy-Weinberg equilibrium. The geno-
type and allele distribution of rs2234693 had no signifi-
cant differences when comparing cases and controls,
even in the subgroups stratified by gender (Table 1). No
significant differences were demonstrated for the geno-
type and allele distribution of rs9340799 in comparing
cases and controls. But when stratified according to gen-
der, a nominal difference was found for genotype distri-
bution and a significant difference for allele distribution
in male cases with schizophrenia and male controls
(corrected p = 0.05 and p = 0.02, respectively), but no
significant differences when comparing for females
(Table 1). This study had the power of 0.739 overall.
Association of haplotypes with schizophrenia
In all samples, a modest linkage disequilibrium was ob-
served between rs2234693 and rs9340799 (D’ = 0.479,Controls p-value
N HWE (p) Genotype MAF Genotype Allele
TT TC CC
292 0.71 111 141 40 0.14 0.868 0.612
146 0.46 60 71 15 0.10 0.894 0.876
146 1.00 51 70 25 0.17 0.692 0.574
AA AG GG
292 0.85 189 93 10 0.03 0.938 0.789
146 0.53 104 40 2 0.01 0.025 0.010
146 1.00 85 53 8 0.05 0.057 0.031
.05.
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in the analysis of normal controls (D’ = 0.982, r2 = 0.380),
but not for patients with schizophrenia (D’ = 0.107, r2 =
0.002) (Figure 1). A haplotype was constructed from
rs2234693 and rs9340799. Four haplotypes were recog-
nized after combining with the two polymorphisms. T-A
was the most prevalent haplotype, with frequencies of
0.5502, 0.5633, and 0.5403 in all, male, and female sub-
jects, respectively, followed by the C-A, C-G, and T-G
haplotypes (Table 2). In all and female subjects, the fre-
quencies of C-A, C-G, and T-G showed a significant dif-
ference between cases and controls, whereas in the male
subjects, only C-A was significantly different (corrected
p = 0.0036). In addition, significant associations of glo-
bal haplotype with schizophrenia showed up in both
males and females (corrected p < 0.0001).
Age at onset analysis
The rs2234693 polymorphism may be related to age at on-
set in the association analysis of ESRα and initial clinical
features of schizophrenia (p = 0.0089) (Figure 2A). The
ages at onset of T-allele carriers and those of noncarriers
were 24.2 ± 7.4 and 27.5 ± 9.1, respectively. When strati-
fied by gender, the association was more significant in the
female cases (p = 0.001, 25.2 ± 6.2, and 31.0 ± 9.8 years for
the T-allele carriers and noncarriers, respectively) (Figure 2-
B), but not in the male cases (p = 0.663). For rs9340799,
no significant association was found in any groups.
Association of SNPs with clinical symptoms
Of 201 patients with schizophrenia enrolled in this ana-
lysis, the distributions of rs2234693 (CC = 31, CT = 99,
and TT = 71) and rs9340799 (AA = 133, AG = 60 and
GG = 8) genotypes were in Hardy-Weinberg equilibrium
(p = 0.77 and p = 0.65, respectively). Clinical symptoms,
including the baseline of total, positive symptom, nega-
tive symptom, and general psychopathology symptom
were analyzed in this study first. There was noFigure 1 Linkage disequilibrium among rs2234693 and
rs9340799. A, linkage disequilibrium in all samples with 0.479 for D’;
B, linkage disequilibrium in patients with 0.107 for D’; C, linkage
disequilibrium in controls with 0.982 for D’.significant difference in total, positive, or negative scores
when comparing diverse genotypes of rs2234693 (data
not shown). However, in comparing the general psycho-
pathology scores, the difference was significant among
TT (40.49 ± 5.81), TC (43.22 ± 5.37), and CC (45.58 ±
7.09) genotypes of rs2234693 only in male patients with
schizophrenia (Table 3). Furthermore, the subscores of
general psychopathology symptoms were examined in all
stratified patients. The CC genotype carriers of
rs2234693 had much higher scores (3.35 ± 1.56) than
T-allele carriers (TC, 2.40 ± 1.45; TT, 2.39 ± 1.47) in
poor impulse control (G14), and the difference still
existed in the paranoid patients (Table 3). In addition,
the tension (G4) of general psychopathology subscores
was significant higher in the CC (3.21 ± 1.53) genotype
carriers than in the T-allele carriers (TC, 2.55 ± 1.47;
TT, 2.18 ± 1.30), only in the paranoid patients
(Table 3). None of the clinical variables of the baseline
symptoms was significantly different between the various
genotypes of rs9340799 (Additional file 1: Table S1).
Association of SNPs with therapeutic effect
The associations of rs2234693 with general psychopath-
ology, tension (G4), and poor impulse control (G14)
score of PANSS have been verified above. Thus, we fur-
ther investigated whether rs2234693 is related to im-
provement in these symptoms after 6 weeks of
antipsychotic treatment. Thereby, the percentage reduc-
tion of general psychopathology score was higher in the
C-allele carriers than TT-homozygote carriers in female
(CC+CT, 0.456 ± 0.270; TT, 0.327 ± 0.216) and paranoid
(CC+CT, 0.464 ± 0.241; TT, 0.367 ± 0.213) patients with
schizophrenia (Table 4). Furthermore, the reduction of
G14 was higher in the CC-homozygote carriers than in
the C-allele carriers overall (CC, 1.900 ± 1.795; CT+TT,
1.020 ± 1.287), male (CC, 2.170 ± 2.125; CT+TT, 1.040 ±
1.272), and paranoid (CC, 2.000 ± 1.888; CT+TT, 0.990 ±
1.289) patients with schizophrenia (Table 4). In addition,
to control for possible confounding effects of the thera-
peutic drug, the patients were stratified by antipsychotic
drug. Interestingly, the CC-homozygote carriers (1.800 ±
1.265) showed a greater G4 reduction than did the CT
(0.900 ± 1.357) and TT (0.550 ± 0.905) genotype carriers
after treatment by aripirazole, while CC-homozygote car-
riers (2.380 ± 1.628) had more G14 reduction than did CT
(1.350 ± 1.336) and TT (0.860 ± 1.332) genotype car-
riers after treatment by risperidone (Table 4). None of
the clinical variables of the reductions was significantly
different between genotypes of rs9340799 (Additional
file 2: Table S2).
Discussion
We conclude that the ESRα rs2234693 and rs9340799
polymorphisms do not substantially contribute to
Table 2 The rs2234693-rs9340799 haplotype association analysis




All T A 0.478 0.620 0.550 1 < 0.0001
C A 0.323 0.187 0.253 0.45 (0.33 - 0.61) < 0.0001
C G 0.070 0.191 0.133 1.94 (1.23 - 3.06) 0.0046
T G 0.130 0.002 0.064 0.01 (0.00 - 0.10) < 0.0001
Male T A 0.473 0.654 0.563 1 < 0.0001
C A 0.294 0.195 0.244 0.47 (0.30 - 0.73) 0.0009
C G 0.058 0.151 0.105 1.75 (0.83 - 3.69) 0.14
T G 0.176 0.000 0.088 0.00 (−Inf - Inf) 1
Female T A 0.490 0.585 0.540 1 < 0.0001
C A 0.344 0.179 0.259 0.44 (0.28 - 0.68) 0.0002
C G 0.090 0.232 0.163 2.04 (1.18 - 3.53) 0.012
T G 0.076 0.004 0.037 0.04 (0.01 - 0.35) 0.0035
Boldface letters represent that the Bonferroni corrected p-values are still less than 0.05.
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ciation was detected in males only for rs9340799. The
results are nearly consistent with most previous studies.
This difference may be due to these reasons: on one
hand, the subjects in the study of Weickert were African
American [26] only, while others were East Asians
[28,34] or southern Europeans [27]. Susceptibility to the
disease and distribution of the genotype for rs2234693
were distinctly different in these subjects (data was from
International HapMap Project). On the other hand, the
sample size and test power between these studies were
difference. Interestingly, the haplotypes in the gene may
increase the risk of schizophrenia. C-A rarely emerges
with the extremely high frequency of approximately
25%, and it may contribute to schizophrenia. It is note-
worthy that C-G may play the role of protective haplo-
type, especially in females. It is also meaningful that T-G
and C-G may act only on females, not males.
The age of onset has been considered the single most
valuable characteristic of schizophrenia that may yield a
clue to its origin [30]. A genomewide linkage study byFigure 2 The Kaplan-Meier plot showing the age at onset of schizoph
T allele of rs2234693; B, the earlier age at onset in female cases carrying thCardno et al. [35] has confirmed a genetic contribution
to the age at onset of schizophrenia. This was the first
time that significant associations of ESRα polymor-
phisms with age at onset of schizophrenia have been
demonstrated. But in the study by Ouyang et al. [34], this
association was not clearly verified. This inconsistency
might be due to differences in population and in the defin-
ition of age at onset. In the present study, it is interesting
that the T-allele of rs2234693 may relate to earlier patho-
genesis of schizophrenia in all and female patients, not in
males independently. Evidence that female schizophrenics
are more easily influenced by inheritance than males may
contribute to the gender difference [36].
Although many genes do not alter susceptibility to
schizophrenia, they may affect clinical features [37,38].
A study by Alonso et al. [32] verified that rs34535804
and five SNP haplotypes in ESRα were associated only
with the psychopathic symptoms contamination obses-
sions and cleaning compulsions. In our study, we
hypothesize that all, male, and paranoid schizophrenic
patients with the T-allele had generally poor impulserenia with T allele. A, the earlier age at onset in all cases carrying the
e T allele of rs2234693.
Table 3 Association analysis of rs2234693 with the base line of symptoms
Group Characteristic Codominant Dominant Recessive
F/χ2 p-value F/χ2 p-value F/χ2 p-value
All General psychopathology score 0.671 0.512 0.186 0.666 1.345 0.248
Tension score 2.407 0.093 0.031 0.859 4.561 0.034
Poor impulse control score 5.506 0.005 1.132 0.289 11.065 0.001
Male General psychopathology score 4.345 0.016 1.476 0.228 4.303 0.041
Tension score 0.915 0.405 0.011 0.915 1.733 0.191
Poor impulse control score 3.367 0.039 0.073 0.788 5.505 0.021
Female General psychopathology score 0.543 0.582 1.069 0.303 0.025 0.875
Tension score 1.469 0.235 0.007 0.934 2.763 0.099
Poor impulse control score 3.458 0.035 3.244 0.074 5.558 0.020
Paranoid General psychopathology score 1.430 0.242 0.035 0.853 2.762 0.098
Tension score 5.208 0.006 0.341 0.560 7.968 0.005
Poor impulse control score 5.613 0.004 0.718 0.398 11.268 0.001
Boldface letters represent that the Bonferroni corrected p-values are still less than 0.05.
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trol symptoms, respectively, suggesting an association of
these psychopathic symptoms with rs2234693 of ESRα
in special populations. In the therapeutic effect analysis,
female and paranoid patients with the CC homozygote
had a superior therapeutic effect in general psychopath-
ology symptom after 6 weeks. Notably, we found that
aripriazole was more effective in treating tension symp-
toms in patients with the CC homozygote, while risperi-
done controlled poor impulse symptoms, again, in
patients having the CC homozygote. These findings sug-
gest that T-allele protects against the onset of these
symptoms, especially in general psychopathology, ten-
sion, and poor-impulse control psychopathic symptoms.
Furthermore, CC-homozygote carriers seem to be more
sensitive to antipsychotic treatment. It is also worthTable 4 Association analysis of rs2234693 with therapeutic ef
Group Characteristic
All Percentage reduction in general psychopathology score
Reduction in tension score
Reduction in poor impulse control score
Male Percentage reduction in general psychopathology score
Reduction in tension score
Reduction in poor impulse control score
Female Percentage reduction in general psychopathology score
Reduction in tension score
Reduction in poor impulse control score
Paranoid Percentage reduction in general psychopathology score
Reduction in tension score
Reduction in poor impulse control score
Aripirazole Percentage reduction in general psychopathology score
Reduction in tension score
Reduction in poor impulse control score
Risperidone Percentage reduction in general psychopathology score
Reduction in tension score
Reduction in poor impulse control score
Boldface letters represent that the Bonferroni corrected p-values are still less than 0noting that two polymorphisms are closely located on
the ESRα gene, but this study has demonstrated that
rs2234693 is not linked in disequilibrium with
rs9340799 in patients with schizophrenia. This explains
why only rs2234693 without rs9340799 is associated
with clinical characteristics of schizophrenia.
ESRα is markedly different from other neurotransmit-
ter receptors in that it may influence mood, cognition,
and synaptogenesis and be involved in neuroprotective
effects [9,39]. ESRα, as a ligand-dependent transcription
factor, is widely distributed in the amygdala-hippocampal
area, periamygdaloid cortex, and posterior cortical nucleus
of the brain [40], especially in several limbic structures,
suggesting its relationship with the above-mentioned pro-
cesses [41]. Furthermore, in the CNS, ESRα binds its spe-
cific ligand estrogen to influence various neurotransmitterfects in 6-week therapy
Codominant Dominant Recessive
F/X2 p-value F/X2 p-value F/X2 p-value
2.964 0.054 5.259 0.023 0.003 0.955
1.879 0.155 0.693 0.406 3.718 0.055
1.928 0.165 4.153 0.043 10.721 0.001
0.290 0.749 0.508 0.478 0.246 0.621
1.482 0.233 0.599 0.441 2.938 0.090
0.157 0.692 0.330 0.567 6.657 0.012
3.784 0.026 6.168 0.015 0.123 0.727
0.562 0.572 0.148 0.701 1.129 0.290
3.946 0.022 5.604 0.020 4.514 0.036
3.264 0.041 6.567 0.011 0.636 0.426
2.339 0.100 0.223 0.637 4.670 0.032
1.163 0.281 3.442 0.065 10.756 0.001
1.321 0.272 2.316 0.132 1.148 0.287
5.721 0.005 4.920 0.029 9.731 0.002
1.019 0.365 0.538 0.465 1.989 0.162
2.213 0.115 1.797 0.183 1.274 0.262
0.591 0.555 1.136 0.289 0.295 0.588
6.632 0.002 6.035 0.016 10.423 0.002
.05.
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epinephrine. These phenomena may be responsible for
the relation between ESRα and many psychiatric disorders
such as schizophrenia [40]. A previous review by
Herrington et al. [42] has summarized the associations of
ESRα polymorphisms with mood and cognition dysfunc-
tion, suggesting a strong relationship between them. We
conclude that the association mechanism of ESRα variants
with psychiatric characteristics may involve the estrogen-
estrogen receptor effect, above. Whether our results can
explain this mechanism needs further study.
In this study, we found a significant association of
ESRα polymorphism with age at onset, general psycho-
pathology symptoms, and, for the first time, the thera-
peutic effects in schizophrenia, but limitations also
existed. Firstly, as only two polymorphisms were selected
for analysis, they do not represent the whole gamut of
the human ESRα, further studies should be done to
analyze more variants. Secondly, not all the patients
were included in the association analysis of clinical vari-
ables due to the finite clinical data. Thirdly, because the
structured clinical interviews were difficult and time-
consuming, our sample size was inadequate and could
easily have led to false positive or negative results.
Fourthly, although stratified analyses were performed,
more subtle and stratified analyses should be used in
further studies. Finally, whether ESRα variants can be
considered as genetic markers to determine the risk or
prognosis of schizophrenia needs further exploration.
Conclusions
Our findings suggest that the haplotypes consisting of
rs2234693 and rs9340799 in ESRα are mainly associated
with schizophrenia. The rs2234693 polymorphism is re-
lated to the age at onset of schizophrenia. Notably, ESRα
may affect the general psychopathology symptoms and
its improvement in specific patients with schizophrenia.
Additionally, we noticed that tension and poor impulse
control symptoms were improved more significantly in
CC-homozygote carriers after treatment by aripirazole
and risperidone, respectively.
Additional files
Additional file 1: Table S1. Association analysis of rs9340799 with the
base line of symptoms.
Additional file 2: Table S2. Association analysis of rs9340799 with
therapeutic effects in 6-week therapy.
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